The pharma giant will license drug-delivery technologies from Vivtex to develop next-generation oral medicines for obesity, diabetes and associated diseases.
Source link
About The Author
Novo Nordisk, Vivtex to Develop Obesity Drugs in Deal Valued at Up to $2.1 Billion